Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19

Benzinga Newsdesk www.benzinga.com Neutral 59.1%

Neg 0% Neu 59.1% Pos 0%

Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $15 to $19.